Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Towards the Improvement of the Treatment of Acute Relapses in Multiple Sclerosis: A Randomized Double-blind, Non-inferiority Controlled Trial Comparing Intranasal Versus Intravenous Methylprednisolone

NCT06223074 is registered in ClinicalTrials.gov with Universidad Nacional Autonoma de Mexico as lead sponsor.

NCT NCT06223074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06223074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Towards the Improvement of the Treatment of Acute Relapses in Multiple Sclerosis: A Randomized Double-blind, Non-inferiority Controlled Trial Comparing Intranasal Versus Intravenous Methylprednisolone
Lead sponsor
Universidad Nacional Autonoma de Mexico
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
January 9, 2023
Completion date
July 5, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis relapsing remitting, treatment